Anaptysbio, INC Form 4 insider transactions

Director Rita Jain acquired stock options and restricted stock units in AnaptysBio, Inc. on January 7, 2025.

Director Magda Marquet reports acquisition of stock options and restricted stock units in AnaptysBio, Inc.

Director John A. Orwin reports acquisition of stock options and restricted stock units in AnaptysBio, Inc.

Director Hollings Renton of AnaptysBio, Inc. was granted stock options and restricted stock units on January 7, 2025.

Director John P. Schmid of AnaptysBio, Inc. was granted stock options and restricted stock units on January 7, 2025.

Director Ware J. Anthony of AnaptysBio, Inc. reports acquisition of stock options and restricted stock units (RSUs) on January 7, 2025.

AnaptysBio's CEO, Daniel Faga, reports the vesting of restricted stock units, acquisition of shares under the ESPP, and related tax withholding transactions.

EcoR1 Capital, along with Oleg Nodelman, has increased its indirect holdings in AnaptysBio through a series of open market purchases of common stock.

AnaptysBio director Renton Hollings exercised stock options and sold 10,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Paul F. Lizzul of AnaptysBio, Inc. reports the exercise of stock options and subsequent sale of shares on September 23, 2024.

Director John A. Orwin reports the vesting and disposal of restricted stock units in AnaptysBio, Inc.

Eric Loumeau, Chief Legal Officer of AnaptysBio, Inc., executed stock options and sold shares to cover tax obligations, while also engaging in sales under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer of AnaptysBio, Paul F. Lizzul, reports acquisition and disposal of company stock to cover tax obligations.

AnaptysBio's CFO, Dennis Mulroy, reports the acquisition and disposal of common stock and derivative securities, including transactions to cover tax obligations and those executed under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Paul F. Lizzul of AnaptysBio, Inc. reports the acquisition and disposal of common stock on August 14, 2024, according to a Form 4 filing.

EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., reports an increase in their holdings of AnaptysBio, Inc. common stock through a purchase at $36.5 per share.

AnaptysBio's CEO, Daniel Faga, acquired 160,000 performance stock units (PSUs) on July 22, 2024, contingent upon achieving certain share price metrics.

Paul F. Lizzul, Chief Medical Officer of AnaptysBio, Inc., acquired 50,000 performance stock units (PSUs) on July 22, 2024, contingent upon the achievement of certain share price metrics.

Dennis Mulroy, CFO of AnaptysBio, Inc., acquired 20,000 shares of common stock on July 22, 2024, through the vesting of performance stock units (PSUs).

Eric Loumeau, Chief Legal Officer of AnaptysBio, Inc., acquired 20,000 shares of common stock on July 22, 2024, through the vesting of performance stock units.

Chief Medical Officer of AnaptysBio, Paul F. Lizzul, reports acquisition and disposal of company stock, including shares acquired through the Employee Stock Purchase Plan (ESPP) and sales under a pre-arranged trading plan.

Director Hollings Renton exercised stock options and sold shares of AnaptysBio, Inc. on July 15, 2024, according to a Form 4 filing.

Director Dennis Fenton sold 1,950 shares of AnaptysBio (ANAB) common stock at $23.17 per share on June 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Dennis M Fenton of AnaptysBio, Inc. reports the vesting and disposal of 3,900 shares of common stock related to restricted stock units on June 15, 2024.

Director Magda Marquet reports the acquisition and disposal of AnaptysBio common stock and restricted stock units on June 15, 2024.

Director John P. Schmid reports the acquisition and disposal of AnaptysBio common stock and restricted stock units on June 15, 2024.

Director Ware J. Anthony reports the disposition of 3,900 shares of AnaptysBio common stock and the vesting of 3,900 restricted stock units on June 15, 2024.

Director John A. Orwin reports the vesting and disposal of 2,035 shares of AnaptysBio common stock related to restricted stock units.

Director Hollings Renton of AnaptysBio, Inc. reports the acquisition and disposal of common stock and restricted stock units.

Director Rita Jain disposed of common stock and restricted stock units of AnaptysBio on June 15, 2024, according to a Form 4 filing.